GEN Exclusives

More »

GEN News Highlights

More »
Dec 10, 2007

ImmunoVaccine Technologies to Take Over Immunotope

  • ImmunoVaccine Technologies (IVT) plans to acquire Immunotope under a binding memorandum of understanding. The transaction will allow IVT to create a pipeline of therapeutic cancer and infectious disease specific vaccines, according to the companies.

    IVT focuses on the commercialization of its VacciMax® platform, which reportedly delivers long duration of immunity in a single administration without boosting or significant side effects. VacciMax will be combined with Immunotope's portfolio of immunotherapeutic antigens, which will be developed for the treatment of cancer and chronic viral infections.

    “The complementary scientific and management skills of IVT and Immunotope will enable us to leverage our respective strengths and increase our capability to develop therapeutic and prophylactic vaccines,” remarks Ramila Philip, Ph.D., president and CSO of Immunotope. “Therapeutic cancer vaccines that combine the right antigens with a powerful delivery system have the potential to treat cancer early and prevent recurrence.”

    The companies expect to complete the acquisition by June 2008.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »